Dermatology Times

AUGUST 23, 2023

While botulinum toxin has emerged as a treatment course for rosacea in recent years, researchers are calling for more comprehensive and detailed long-term research to assess its effectiveness.

Rosacea 69

Rosacea Safety Clinic Treatments 69

Dermatology Times

MARCH 10, 2024

Shawn Kwatra, MD, presented late-breaking data at AAD 2024 on the largest prurigo nodularis and nemolizumab clinical trial, OLYMPIA.

Safety 78

Safety Clinic 78

Dermatology Times

MAY 30, 2024

Novartis announced late-breaking data for the BTK inhibitor at the 2024 European Academy of Allergy and Clinical Immunology Congress.

Sustainability 73

Sustainability Safety Clinic 73

Dermatology Times

OCTOBER 12, 2023

Clinical response was maintained at 73.2% for PASI-75 in POETYK PSO long-term extension trial.

Safety 78

Safety Clinic 78

Atelier Esthetique Institute of Esthetics

DECEMBER 5, 2023

Accrediting committees ensure that the quality and safety of your school is approved and noted by outside bodies. Atelier Esthetique has a clinic where our students can work for the general public. Thankfully, Atelier Esthetique Institute can help with our robust curriculum.

Esthetician 148

Esthetician Esthetics Education Training 148

Dermatology Times

JANUARY 4, 2024

The BLA submission for DMB-3115 is rooted in phase III multi-regional clinical trials focusing on plaque psoriasis patients. The results demonstrated a high similarity between DMB-3115 and ustekinumab in terms of quality, safety, and efficacy.

Safety 78

Safety Clinic 78

Kim Gallo Esthetics

DECEMBER 23, 2022

At Kim Gallo Esthetics, your comfort and safety is our top priority. It's hand-made here in the USA, FDA-cleared, and has been clinically proven to be effective. Microcurrent facials are considered to be very safe and can be used on all skin types.

Facials 195

Facials Esthetics Skin Types Collagen 195

Dermatology Times

APRIL 5, 2024

Researchers reviewed the efficacy and safety of omalizumab in patients with severe CSU in a routine clinical practice setting.

Safety 74

Safety Clinic 74

Dermatology Times

OCTOBER 24, 2024

Findings from 2 phase 3 trials indicate that ZORYVE cream significantly improves both clinical outcomes and quality of life in patients with mild to moderate atopic dermatitis.

Safety 53

Safety Dermatitis Clinic 53

Dermatology Times

JUNE 10, 2024

Phase 3 clinical results showed that the safety and tolerability profiles were consistent with those observed in the original pivotal trials.

Safety 74

Safety Clinic 74

Dermatology Times

JUNE 2, 2024

Raj Chovatiya, MD, PhD, focused on understanding JAK inhibitors, discussing their clinical use and safety profiles for effective patient communication.

Safety 73

Safety Clinic 73

The Dermatology Digest

NOVEMBER 20, 2024

. “The approval of BIMZELX in moderate-to-severe hidradenitis suppurativa is welcome given the substantial unmet clinical needs and limited number of treatment options available today,” says investigator and lead author of the studies, Alexa B. Clinical responses were sustained to Week 48.

Safety 78

Safety Sustainability Clinic Medical 78

Dermatology Times

OCTOBER 2, 2023

No concerns were cited about the clinical data package, safety, or label of lebrikizumab.

Safety 78

Safety Clinic 78

Online Laser Training

OCTOBER 11, 2019

Department of Dermatology, Aalborg University Hospital, Aalborg, Denmark where he plans to assist Clinical Professor of Dermatology Peter Bjerring MD, Dr.Sci., Department of Clinical Medicine at Aalborg University Hospital to build a new dermatological research area with collaboration with other specialities.

Hospital 78

Hospital Safety Clinic Training 78

Online Laser Training

OCTOBER 11, 2019

Department of Dermatology, Aalborg University Hospital, Aalborg, Denmark where he plans to assist Clinical Professor of Dermatology Peter Bjerring MD, Dr.Sci., Department of Clinical Medicine at Aalborg University Hospital to build a new dermatological research area with collaboration with other specialities.

Hospital 78

Hospital Safety Clinic Training 78

The Dermatology Digest

FEBRUARY 14, 2024

“We are thankful to the patients and medical experts whose insights informed our clinical trials, which assessed nemolizumab’s ability to reduce the symptoms of itch and skin lesions. In the ARCADIA program, nemolizumab clinically improved skin lesions and rapidly improved itch and sleep disturbance.

Dermatitis 78

Dermatitis Clinic Safety Dermatology 78

Dermatology Times

OCTOBER 3, 2024

Brad Glick, DO, MPH, discusses how to effectively introduce photodynamic therapy (PDT) into a dermatology clinic by outlining necessary equipment and setup, providing guidance on essential patient discussions for treatment introduction, and sharing strategies to ensure treatment efficacy while prioritizing patient safety and satisfaction.

Clinic 36

Clinic Therapy Safety Dermatology 36

The Dermatology Digest

MAY 17, 2024

Deucravacitinib (Sotyktu, Bristol Myers Squibb) showed durable response rates and consistent safety in patients with moderate-to-severe plaque psoriasis after four years of continuous treatment, according to results from the POETYK PSO long-term extension (LTE) trial. patient-years (PYs) for the safety analyses. Year 4, 0.1)

Safety 36

Safety Sustainability Clinic Innovations 36

The Dermatology Digest

DECEMBER 13, 2024

This approval is based on positive results from the phase III ARCADIA clinical trial program which evaluated the efficacy and safety of nemolizumab in combination with background TCS, with or without TCI, versus placebo in combination with TCS, with or without TCI, in 1,728 patients aged 12 or older with moderate to severe atopic dermatitis.

Dermatitis 66

Dermatitis Safety Eczema Dermatology 66

The Dermatology Digest

APRIL 12, 2024

Recent cases where possibly counterfeit neurotoxins in Illinois and Tennessee led to a cluster of illnesses resembling Botulism highlight the need to strengthen patient safety through increased oversight of medical care in all settings, according to the American Society for Dermatologic Surgery Association (ASDSA).

Safety 69

Safety Surgery Medical Training 69

The Dermatology Digest

FEBRUARY 11, 2024

A meta-analysis of 45 randomized clinical trials comprised of 12,996 patients disclosed neither an increased risk of major cardiovascular events (MACE) such as heart attack and stroke) nor of venous thromboembolic events (VTE). This particular study did not address other safety concerns, such as all-cause mortality, infections, or cancer.

Dermatology 74

Dermatology Safety Clinic Therapy 74

Dermatology Times

OCTOBER 27, 2024

Deucravacitinib demonstrated significant efficacy and safety in treating moderate to severe scalp psoriasis, as shown in the PSORIATYK SCALP trial presented at Fall Clinical.

Safety 36

Safety Clinic 36

The Dermatology Digest

MARCH 18, 2024

Srinivas Sidgiddi, MD, Vice President, Research & Development at Journey Medical, adds, “The NDA submission is supported by positive data from Journey Medical’s two DFD-29 Phase 3 clinical trials for the treatment of rosacea.

Rosacea 74

Rosacea Medical Office Clinic 74

The Dermatology Digest

JULY 18, 2024

More on the DMT310 Phase 3 Clinical Program Design The DMT310 Phase 3 clinical program will include two Phase 3 clinical trials to evaluate the efficacy, safety, and tolerability of DMT310 in patients with moderate-to-severe facial acne. Food and Drug Administration.

Clinic 36

Clinic Dermatology Collagen Exfoliation 36

Southeastern Esthetics Institute

AUGUST 23, 2016

Thorough organization of charting systems, patient and employee safety and sanitation practices, and consistent monitoring by supervisory staff is the key to medical spa success. Proper communication is exceptionally important between the physician and support staff when treating patients in a medical setting.

Esthetician 195

Esthetician Esthetics Document Office 195

The Dermatology Digest

AUGUST 13, 2024

More data will be needed to define the safety profile of JAK inhibitors in Down syndrome, and we look forward to the completion of the trial and analysis of the full dataset.”

Clinic 74

Clinic Safety Dermatitis Medical 74

The Dermatology Digest

APRIL 16, 2024

The FDA approval of Selarsdi, referred to as AVT04 during development, was based on a totality of evidence, including analytical and clinical data.

Partnerships 74

Partnerships Injections Safety Marketing 74

The Dermatology Digest

JULY 14, 2024

CUTISS AG’s denovoSkin performed well in a Phase 2 clinical trial of patients undergoing reconstructive skin surgery for various conditions, according to an interim analysis of the data. Following the announced positive primary endpoint in Q1 2023, the one-year readout evaluated long term safety and scar quality.

Surgery 73

Surgery Scarring Safety Clinic 73

The Dermatology Digest

JANUARY 15, 2024

Delgocitinib cream continues to perform well in chronic hand eczema (CHE) with limited systemic exposure, according to two studies presented at the 2024 Winter Clinical Dermatology Conference in Honolulu, Hawaii. The post New Research Supports the Safety and Efficacy of Delgocitinib in CHE appeared first on The Dermatology Digest.

Safety 36

Safety Eczema Dermatology Treatments 36

Dermatology Times

DECEMBER 5, 2024

James Song, MD, discusses how clinical trial data demonstrates the risk-benefit profile of vitiligo therapies, with particular focus on balancing potential adverse effects of Janus kinase inhibitors against their proven efficacy in achieving repigmentation.

Safety 36

Safety Therapy Clinic 36

The Dermatology Digest

DECEMBER 18, 2024

The clinical results demonstrated that STEQEYMA and its reference product, ustekinumab, are highly similar, and have no clinically meaningful differences in terms of safety and efficacy. “STEQEYMA is now the latest biologic in our immunology portfolio, joining ZYMFENTRA (infliximab-dyyb).

Portfolios 68

Portfolios Injections Office Safety 68

The Dermatology Digest

JUNE 5, 2024

The randomized, double-blind, vehicle-controlled trial will evaluate the safety and efficacy of once-daily VYN201 topical gel in three dose cohorts (1%, 2% and 3% concentrations) compared to vehicle for 24 weeks. Check out TDD’s one-on-one interview with Iain Stuart, PhD , Chief Scientific Officer at Vyne Therapeutics.

Safety 73

Safety Office Facials Therapy 73

The Dermatology Digest

JULY 24, 2024

This BLA/MAA for BAT2206 is based on the totality of evidence comprising a comprehensive analytical, non-clinical and clinical data package. A Biologics License Application seeking approval for BAT2206 is also currently under review by the China National Medicinal Product Administration (NMPA).

Dermatology 78

Dermatology Sales Marketing Safety 78

The Dermatology Digest

JULY 29, 2024

is initiating the Onward Phase 3 Clinical Program evaluating ESK-001, an oral tyrosine kinase 2 (TYK2) inhibitor, in moderate-to-severe plaque psoriasis. Key secondary endpoints will include PASI 90, PASI 100 and sPGA 0 measured at Weeks 16 and 24, and safety and tolerability. Alumis Inc.

Clinic 36

Clinic Safety Office Treatments 36

The Dermatology Digest

MAY 16, 2024

trial site in MoonLake Immunotherapeutics’ global Phase 3 clinical program, VELA, evaluating sonelokimab in hidradenitis suppurativa (HS). We are making significant progress in establishing clinical trial sites to enroll 800 patients, and we eagerly anticipate reporting the week 16 primary endpoint readout around mid-2025.”

Safety 68

Safety Clinic Dermatology Office 68

Dermatology Times

SEPTEMBER 25, 2023

Lilia Correa-Selm, MD, FAAD, FACMS, reviews the clinical trial data relating to the EVRIANCE study examining the use of vismodegib treatment in patients with locally advanced basal cell carcinoma, highlighting key efficacy and safety endpoints.

Safety 36

Safety Clinic Treatments 36

The Dermatology Digest

JANUARY 20, 2024

The study is designed to assess the safety, tolerability, and pharmacokinetics, of orally administered EVO756. Evommune’s pre-clinical data demonstrates that by blocking activation of MRGPRX2 and degranulation of mast cells, EVO756 has the potential to be a first-in-class oral treatment for a variety of mast cell-mediated diseases.

Safety 74

Safety Office Dermatitis Clinic 74